PERCUTANEOUS REVASCULARIZATION IN MULTIVESSEL CORONARY DISEASE IS IMPROVED WITH EVEROLIMUS-ELUTING STENT DEPLOYMENT: POOLED ANALYSIS FROM THE SPIRIT II IIIIV AND COMPARE TRIALS  by Kereiakes, Dean J. et al.
    
  i2 SUMMIT   
E1643
JACC April 5, 2011
Volume 57, Issue 14
PERCUTANEOUS REVASCULARIZATION IN MULTIVESSEL CORONARY DISEASE IS IMPROVED WITH 
EVEROLIMUS-ELUTING STENT DEPLOYMENT: POOLED ANALYSIS FROM THE SPIRIT II, III, IV AND 
COMPARE TRIALS
i2 Oral Contributions
Ernest N. Morial Convention Center, Room 353
Monday, April 04, 2011, 8:14 a.m.-8:28 a.m.
Session Title: DES II
Abstract Category: 16. PCI - DES (clinical/outcomes)
Presentation Number: 2905-6
Authors: Dean J. Kereiakes, Pieter C. Smits, Elvin Kedhi, Helen Parise, Martin Fahy, Patrick W. Serruys, Gregg W. Stone, The Christ Hospital Heart and 
Vascular Center/The Lindner Research Center, Cincinnati, OH, Columbia University Medical Center/Cardiovascular Research Foundation, New York, NY
Background: The SYNTAX trial demonstrated greater relative benefit of surgical (CABG) compared with percutaneous (PCI) coronary 
revascularization using paclitaxel-eluting stents (PES) in patients with complex multivessel coronary artery disease (CAD). CABG benefit was in large 
part driven by differences in revascularization and/or myocardial infarction (MI).
Methods: To determine whether a 2nd generation stent design might improve outcomes following PCI in multivessel CAD, pooled patient level 
data through 2 years follow-up were analyzed from the SPIRIT II, III, IV and COMPARE randomized comparative trials of PES versus everolimus eluting 
stent (EES). Ischemia driven target lesion and vessel revascularization (ID-TLR, ID-TVR), cardiac death (CD) or target vessel MI (TV-MI) and stent 
thrombosis (ST; ARC def/prob) stratified by randomly assigned stent type and number of vessels treated (1 [n=5465 patients] vs ≥ 2 [n=1322 
patients]) at 1 and 2 years follow-up are shown.
Results: Appear in the table.
Conclusion: Pooled patient level data from 4 randomized trials demonstrate significant and progressive improvements in measures of clinical 
restenosis, MI and ST favoring EES compared to PES. The absolute clinical benefit provided by EES is proportional to the complexity of CAD as 
reflected by the number of vessels treated. Use of EES in future randomized comparisons of CABG versus PCI for treatment of complex CAD would 
optimize PCI outcomes.
Follow-up 1 Year 2 Year
# vessels Rx 1 ≥ 2 1 ≥ 2
EES PES EES PES EES PES EES PES
D, MI, ID-TVR 6.1 8.2* 8.8 14.8** 9.5 12.6** 14.9 19.7**
ID-TLR (%) 2.1 4.1† 3.5 7.3* 3.7 5.8** 6.0 9.7*
ID-TVR (%) 3.3 5.0* 5.5 9.8* 5.7 7.9* 9.4 12.6††
CD/TV-MI (%) 2.4 3.7* 3.8 7.6* 3.5 5.6** 5.9 10.4**
Any MI 1.8 3.3** 3.4 6.8* 2.6 4.7† 4.5 8.6*
ST (%) 0.3 1.2† 1.0 2.7†† 0.5 1.8† 1.4 3.8**
††p<0.05 *p<0.01 **p<0.001 †p<0.0001
